Targeting Activin Receptor-like Kinase 2 Using Heterobifunctional Protein Degraders

Area of Science:

• Medicinal Chemistry
• Molecular Biology
• Oncology

Background:

• Activin receptor-like kinase 2 (ACVR1/ALK2) is crucial for bone morphogenetic protein (BMP) signaling pathways.
• Dysregulation of ALK2 is implicated in fibrodysplasia ossificans progressiva (FOP), diffuse intrinsic pontine glioma (DIPG), and glioblastoma.

Purpose of the Study:

• To develop novel chemical degraders targeting ALK2.
• To investigate the therapeutic potential of ALK2 modulation in human diseases.

Main Methods:

• Design and synthesis of first-in-class ALK2 degraders.
• Utilizing M4K3233 as a chemical tool to elucidate ALK2 degradation mechanisms.
• Optimization of lead compounds to enhance ALK2 degradation potency.

Main Results:

• Successful development of M4K3233, a potent and selective ALK2 degrader.
• Identification of M4K3250, a derivative with improved ALK2 degradation efficacy.
• Demonstration of the utility of these compounds in studying ALK2's role in disease.

Conclusions:

• The developed ALK2 degraders, including M4K3250, represent a promising new class of therapeutic agents.
• These compounds offer valuable tools for understanding ALK2-related pathologies.
• The findings support the translational potential of ALK2 degraders in drug discovery for FOP, DIPG, and glioblastoma.